Determining the molecular basis of therapy resistance conferred by genetic lesions in the tumour protein TP53 in haematological malignancies

确定血液系统恶性肿瘤中肿瘤蛋白 TP53 基因损伤所赋予的治疗耐药性的分子基础

• 批准号: nhmrc : 2002618
• 金额: $ 88.52万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/determining-molecular-basis-haematological-malignancies/1779945
• 关键词: Determining; molecular; basis; therapy; resistance

Blood cancers that have genetic lesions in a tumour suppressor protein called TP53 respond poorly to therapy. Curing these patients is extremely challenging and new therapeutic strategies are desperately needed. Here, we aim to uncover the molecular mechanisms of drug resistance caused by loss of TP53 function and rationally design new therapies that may be curative. To do this, our team of leading scientists and clinicians will study patient samples and pre-clinical models of blood cancer.

在一种称为TP53的肿瘤抑制蛋白中存在遗传病变的血癌对治疗反应很差。治愈这些患者极具挑战性，迫切需要新的治疗策略。在这里，我们的目标是揭示TP53功能丧失引起的耐药性的分子机制，并合理设计可能治愈的新疗法。为此，我们的领先科学家和临床医生团队将研究血癌的患者样本和临床前模型。